Literature DB >> 1532807

Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma.

A M Bentley1, P Maestrelli, M Saetta, L M Fabbri, D S Robinson, B L Bradley, P K Jeffery, S R Durham, A B Kay.   

Abstract

We have studied the phenotype and activation status of leukocytes in the bronchial mucosa in patients with isocyanate-induced asthma. Fiberoptic bronchial biopsy specimens were obtained from nine subjects with occupational (five toluene- and four methylene diisocyanate-sensitive) asthma, 10 subjects with extrinsic asthma, and 12 nonatopic healthy control subjects. Bronchial biopsy specimens were examined by immunohistology with a panel of monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase method. There was a significant increase in the number of CD25+ cells (interleukin-2 receptor-bearing cells, presumed "activated" T-lymphocytes; p less than 0.01) in isocyanate-induced asthma compared with that of control subjects. There were also significant increases in major basic protein (BMK-13)-positive (p less than 0.02) and EG2-positive (p less than 0.01) cells that represent total and "activated" eosinophil cationic protein-secreting eosinophils, respectively. In agreement with our previous findings, CD25+ (p less than 0.01), BMK-13 (p less than 0.03), and EG2+ (p less than 0.01) cells were also elevated in extrinsic asthma. No significant differences were observed in the numbers of T-lymphocyte phenotypic markers (CD3, CD4, and CD8) between subjects with asthma (isocyanate-induced and extrinsic) and control subjects. Similarly, no significant differences in immunostaining for neutrophil elastase (neutrophils) or CD68 (macrophages) were observed. The results suggest that isocyanate-induced occupational asthma and atopic (extrinsic) asthma have a similar pattern of inflammatory cell infiltrate. The results support the view that T-lymphocyte activation and eosinophil recruitment may be important in asthma of diverse etiology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532807     DOI: 10.1016/0091-6749(92)90437-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

Review 1.  Effects of anti-IgE in asthmatic subjects.

Authors:  A J Frew
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Gene-environment interactions in asthma.

Authors:  F Castro-Giner; F Kauffmann; R de Cid; M Kogevinas
Journal:  Occup Environ Med       Date:  2006-11       Impact factor: 4.402

Review 3.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 4.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 5.  Skin and respiratory chemical allergy: confluence and divergence in a hybrid adverse outcome pathway.

Authors:  Ian Kimber; Alan Poole; David A Basketter
Journal:  Toxicol Res (Camb)       Date:  2018-01-26       Impact factor: 3.524

Review 6.  Cytokines. 3. Cytokines in asthma.

Authors:  D S Robinson; S R Durham; A B Kay
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

Review 7.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

Review 8.  In vivo models of occupational asthma due to low molecular weight chemicals.

Authors:  J P Hayes; A J Newman Taylor
Journal:  Occup Environ Med       Date:  1995-08       Impact factor: 4.402

Review 9.  Evidence for Th2-type T helper cell control of allergic disease in vivo.

Authors:  D S Robinson; Q Hamid; M Jacobson; S Ying; A B Kay; S R Durham
Journal:  Springer Semin Immunopathol       Date:  1993

Review 10.  Immunosuppressive agents and asthma.

Authors:  T Fukuda
Journal:  Clin Rev Allergy       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.